 Bloomberg | Biogen Idec Management Discusses Q2 2012 Results - Earnings Call Transcript Seeking Alpha Moving on to daclizumab. We completed enrollment in this side, the second registrational trial for daclizumab and relapsing-remitting MS with more than 1800 patients. The trial will determine whether the significant reduction in annualized relapses and ... CORRECTING and REPLACING Biogen Idec Increases Revenue 18% to $1.4 ... Biogen Idec sees revenue surge on MS drug sales |
